Overview

* IDEX ( IEX ) Q3 sales rose 10% to $879 mln, beating analyst expectations

* Adjusted EPS for Q3 was $2.03, exceeding analyst estimates

* Company increased share repurchase authorization to $1 bln

Outlook

* IDEX ( IEX ) narrows full-year 2025 GAAP EPS to $6.35 - $6.40

* Company maintains full-year 2025 organic sales growth at approximately 1%

* IDEX ( IEX ) expects at least 100% free cash flow conversion for full year 2025

Result Drivers

* ACQUISITION IMPACT - Mott acquisition significantly boosted sales, especially in Health & Science Technologies

* SEGMENT PERFORMANCE - Higher volumes in Health & Science Technologies and Fluid & Metering Technologies offset by declines in Fire & Safety/Diversified Products

* COST CONTAINMENT - Operational productivity improvements and cost containment actions supported results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $878.70 $862.27

mln mln (10

Analysts

)

Q3 Beat $2.03 $1.93

Adjusted (10

EPS Analysts

)

Q3 EPS $1.70

Q3 Beat $152.80 $148.91

Adjusted mln mln (6

Net Analysts

Income )

Q3 Beat $239.80 $208.35

Adjusted mln mln (2

EBITDA Analysts

)

Q3 44.50%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for IDEX Corp ( IEX ) is $197.00, about 15.3% above its October 28 closing price of $166.95

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)